Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

• Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension
• HYPER-H21-4 will build on successes witnessed in initial human hypertension studies
• The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease
• Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology

With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of orally-delivered fat-soluble active pharmaceutical ingredients (“APIs”) through its patented DehydraTECH(TM) drug delivery technology  is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over the course of two hours. “The results from the study showed that the generic nicotine benzoate pouch required about 45 minutes to reach its peak delivery rate. In comparison, the DehydraTECH-nicotine benzoate pouch reached peak delivery rates at both eight minutes and again at 30 minutes. It was further noted that in just four minutes after the pouch was placed in the mouth, the DehydraTECH-nicotine had reached a higher delivery level than the generic achieved at any point during the study,” reads a recent article. Lexaria CEO Chris Bunka commented: “Our technology was ten to twenty times faster in delivering comparable levels of nicotine into bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction.” To view the full article, visit https://cnw.fm/zyFFL

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

• Speeds up delivery – the effects of the product are felt by the subject in just minutes.
• Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
• Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
• Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
• Reduces drug administration cost – lower doses mean lower overall drug costs.
• Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

• Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
• Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
• Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
• Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
• Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
• Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Wednesday's trading session at $5.32, up 1.7208%, on 59,407 volume with 351 trades. The average volume for the last 3 months is 59,407 and the stock's 52-week low/high is $3.9751/$12.50.

Recent News

• Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) - Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
• CannabisNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
• Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer's Disease and Diabetes

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

New research has found that white British individuals who have been diagnosed with a malignant brain tumor have a higher risk of mortality than those from other ethnicities. The research’s findings were presented at the NCRI Festival. The study assessed the influence of an individual’s ethnicity on their rate of survival of a brain tumor. The researchers found that individuals who are classified under other ethnic groups had 30% lower chances of mortality in one year after being diagnosed with a malignant brain tumor. The prospects of patients with malignant brain tumors could improve in the coming years as several companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are hard at work trying to come up with better treatments targeting central nervous system and brain cancers.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $1.17, up 5.4054%, on 154,842 volume with 375 trades. The average volume for the last 3 months is 154,852 and the stock's 52-week low/high is $1.04/$4.46.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Study Investigates Influence of Ethnicity on Surviving Brain Tumors
• InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Roundtable
• Study Finds Neuroinflammation Protein Decreases Rate of Survival in Male Patients with Glioblastoma

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently announced the completion of an agreement for the transition of the management at Platinum Vape LLC (“PV”), having settled all additional PV acquisition price considerations. “RWB estimates that production of PV vape carts will increase to over 450,000 in November, a projection that has made expansion of the PV brand a top priority. Michigan and California are proving to be the two vital promising markets pushing for this growth, prompting focus on PV and streamlining its operations,” reads a recent article. The management transition saw the addition of Shea Alderete and Joaquin Rodriguez, both of whom will serve as co-general managers of RWB California’s day-to-day operations, and Craig Rosevear, who will be RWB West U.S. regional controller. RWB also announced “the appointment of two new members to its team: Christopher Ecken and Colby De Zen. Experienced financial executive Chris Ecken becomes the company’s new chief financial officer (‘CFO’), while strategic investor and entrepreneur Colby De Zen becomes the company’s newest board member. This move is being made to strengthen the executive team and its board.” To view the full article, visit https://cnw.fm/12q7u

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

• Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
• High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
• Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

• A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
• Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
• Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Wednesday's trading session at $0.49035, up 11.4432%, on 1,260,410 volume with 244 trades. The average volume for the last 3 months is 1.26M and the stock's 52-week low/high is $0.405/$1.65.

Recent News

• Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) - CannabisNewsBreaks - Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Makes Expansion of Platinum Vape Brand Top Priority
• Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Adding to its Growing Retail Presence with Rapid Developments in Florida
• 420 with CNW - Study Finds That Legalizing Cannabis Doesn't Cause Increase in Traffic Injuries

Laredo Oil Inc. (OTC: LRDC)

The QualityStocks Daily Newsletter would like to spotlight Laredo Oil Inc. (LRDC).

Laredo Oil (OTC: LRDC) is an Austin, Texas-headquartered oil and gas exploration and production (“E&P”) company. Its primary focus is on acquiring, developing and operating undervalued conventional oil and gas properties. Having leased 23,739 mineral acres in the Western Williston Basin of Montana, the company expects to drill the first development well at one of the first of 10 potential locations it has identified before year-end. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. Laredo also continues to take other leases in the area. “The company will focus on value, growth potential, and free cash flow while complying with common ESG [Environmental, Social, and Governmental] policies, often having a lower environmental impact than its competitors through its EOR [Enhanced Oil Recovery] methods,” a recent article reads. “In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its Underground Gravity Drainage(TM) (“UGD”) model to recover oil reserves previously considered to be economically incapable of recovery.” The UGD model, Laredo believes, has significantly lower implementation costs than other commonly used EOR methods. “Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected.” To view the full article, visit https://ibn.fm/ujMyW

Laredo Oil Inc. (OTC: LRDC) is a publicly traded oil and gas exploration and production (E&P) company engaging in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields that are suitable for the company’s proprietary Enhanced Oil Recovery (EOR) methods.

Laredo Oil is headquartered in Austin, Texas.

Conventional Acreage

Laredo Oil’s primary focus is on acquiring, developing, and operating undervalued conventional oil and gas properties.

The company leased 23,739 mineral acres in the Western Williston Basin of Montana, at favorable prices during the most recent down cycle and continues to take leases in the area. Before year end, it expects to drill the first development well at one of the first of 10 potential locations it has identified. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. The company believes the leased acreage has the potential to yield at least five years of development opportunities.

The company intends to pursue aggressively the acquisition of quality assets that major, mid-major, and large independent oil and gas companies continue to divest themselves of at a discount in response to ESG (Environmental, Social and Governmental) & sustainability initiatives and other pressures imposed upon them by their activist boards of directors. The company will focus on value, growth potential and free cash flow while complying with common sense ESG policies, often having a lower environmental impact than its competitors through its EOR methods.

EOR

In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its proprietary Underground Gravity Drainage™ (UGD) model to recover stranded oil reserves (reserves previously considered to be economically incapable of recovery). The UGD method is applicable to mature oil fields that have very specific geological and reservoir characteristics.

Laredo Oil has done extensive research and field level application over the last 10 years and has identified specific oil fields within the United States that it believes are qualified for the UGD recovery method. The company believes the costs of implementing the UGD method are significantly lower than those of other commonly used EOR methods. Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected.

Market Outlook

The company expects U.S. oil prices to climb in the near term as energy demand intensifies with the economy continuing to recover from the COVID-19 slowdown. Also causing upward price pressure is global supply chain dysfunction that slows or prevents shipments, including energy components, from reaching destinations. Domestic oil production is also constrained by years of reduced investment in fossil fuel producers due to green energy mandates. Accordingly, the company believes that the short-term outlook for oil is favorable. Many industries have yet to reach their pre-COVID production levels, which the company believes points to a continuing near-term upward trend in energy demand.

Management Team

Mark See has been the Chief Executive Officer and Chairman of the Board of Directors of the company since October 16, 2009. He has over 30 years’ experience in heavy civil, natural resources and the E&P industries. He was the founder and founding CEO of Rock Well Petroleum, a private oil & gas company until December 2008 and worked from then until October 2009 forming Laredo Oil. He was employed with Albian Sands as the Manager for the Alberta Oil Sands Projects at Fort McMurray, Alberta, Canada, a joint venture between Shell Canada and Chevron. Mr. See was also President of Oil Recovery Enhancement LLC in Bozeman, Montana, a private oil company. He was selected as one of the top 25 Engineers in North America by the Engineering News Record for his innovations in the petroleum industry. He is a graduate of the Mackay School of Mines at the University of Nevada at Reno, with a degree in Mining Engineering. He is a member of the Society of Mining Engineers and the Society of Petroleum Engineers.

Bradley Sparks currently serves as the Chief Financial Officer and Treasurer of Laredo Oil and has been a director of the company since March 1, 2011. Before joining Laredo Oil in October 2009, he was the Chief Executive Officer, President and a Director of Visualant Inc. Prior to joining Visualant, he was the Chief Financial Officer of WatchGuard Technologies Inc. from 2005-2006. Before joining WatchGuard, he was the founder and managing director of Sunburst Growth Ventures LLC, a private investment firm specializing in emerging-growth companies. Previously, he founded Pointer Communications and served as Chief Financial Officer for several telecommunications and internet companies, including eSpire Communications Inc., Digex Inc., Omnipoint Corporation, and WAM!NET. He also served as Vice President and Treasurer of MCI Communications from 1988-1993 and as Vice President and Controller from 1993-1995. Before his tenure at MCI, Mr. Sparks held various financial management positions at Ryder System Inc. He currently serves on the Board of Directors of Comrise. Mr. Sparks graduated from the United States Military Academy at West Point in 1969 and is a former Army Captain in the Signal Corps. He has a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and is a licensed CPA in Florida.

Donald Beckham has served as a director of the company since March 1, 2011. Since July 2015, he has been a partner with Copestone Energy Partners LLC. In 1993, he founded Beckham Resources Inc. (“BRI”), which, for over 30 years, has been a licensed, bonded and insured operator in good standing with the Railroad Commission of Texas. Through BRI, Mr. Beckham has drilled and operated fields for his own account. His expertise is in the acquisition, exploitation, exploration and production enhancement of mature oil and gas fields through which he has been able to enhance production by compressor optimization, pump design, work-over programs, stimulation techniques and identifying new pay zones. Prior to BRI, Mr. Beckham was the chief operations manager for Houston Oil Fields Corporation (“HOFCO”), where he began his career. There, he was responsible for drilling, production and field operations and managed approximately 100 people, including engineers, geologists, land men, pumpers, and other contract personnel, as well as state and federal environmental and regulatory functions. He managed an annual capital budget of approximately $30 million and operated approximately 100 wells. HOFCO drilled about 20 wells per annum and performed approximately 30 recompletions and work over operations each year. HOFCO owned interests in about 10 key fields principally in Texas, and company-managed production was approximately 1,000 bpd of crude oil and 10 mm cfd of natural gas. Mr. Beckham is a petroleum engineer and 1984 graduate of Mississippi State University.

Michael Price, an independent director of Laredo Oil, has over 40 years of senior financial and petroleum experience in the global oil and gas industry. He has been a principal in Octagon Energy Advisors, a Houston-based energy investment advisory firm, from 2002 to the present. The firm advises financial institutions and institutional investors participating in energy investments. From 2008 through his retirement in 2021, he was a Managing Director at ING Capital, which provides debt financing to domestic exploration and production companies. From 1998 through 2002, Mr. Price was the Chief Financial Officer of Forman Petroleum Corporation. Before that, Mr. Price was Managing Director at Chase Manhattan Bank for 15 years and was in charge of technical support for Chase’s worldwide energy merchant banking activities. In his early career, he worked as a consulting principal on domestic petroleum engineering and landowner matters and gained extensive international experience working with major oil companies in a variety of operating positions. He holds a BS and MS from Illinois Institute of Technology, an MBA from the University of Chicago, a M.Sc. from the London School of Economics, and an MS in Petroleum Engineering from Tulane University.

FORWARD-LOOKING STATEMENTS

This press release and the statements made by Laredo Oil, Inc. in this press release may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements describe Laredo Oil’s future plans, projections, strategies and expectations, and may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or the negative versions of those words or other words of similar meaning. These forward-looking statements are based on assumptions and involve a number of risks, uncertainties, situations and other factors that may cause the actual results, level of activity, performance or achievements of Laredo Oil or the oil industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by these statements. These factors include changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in the reports filed with, or furnished to, the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Laredo Oil undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Laredo Oil Inc. (LRDC), closed Wednesday's trading session at $0.09, up 15.3846%, on 13,451 volume with 4 trades. The average volume for the last 3 months is 13,451 and the stock's 52-week low/high is $0.0101/$0.58895.

Recent News

• Laredo Oil Inc. (OTC: LRDC) - InvestorNewsBreaks - Why Laredo Oil Inc. (LRDC) Is 'One to Watch'
• InvestorNewsBreaks - Laredo Oil Inc. (LRDC) Engages IBN for Corporate Communications Expertise
• InvestorNewsBreaks - Laredo Oil Inc. (LRDC) Eyes Expansion Potential for Lustre Oil Field Properties

StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF)

The QualityStocks Daily Newsletter would like to spotlight StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF).

• StraightUp marked 2021 with strategic opportunities in the United States and Peru
• These projects were selected by management based on past exploration and proven reserves in these regions
• 2021 also marked the year StraightUp up-listed to the OTCQB Venture Market in the United States
• StraightUp is optimistic about 2022

For the 2021 fiscal and calendar year, StraightUp Resources (CSE: ST) (OTCQB: STUPF) set out on an aggressive asset acquisition plan, coupled with an exploration program that would be the highlight of the year. Thus far, it has acquired the West Cat Mine in Nevada, along with the Ferdinand Gold Project and Bear Head Gold Project, both located in western Ontario (https://ibn.fm/E2Oho). However, these acquisitions do not aptly represent its commitment to maximizing shareholder wealth as its aggressive exploration program.

StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) is a public company engaged in the business of mineral exploration and the acquisition of mineral property assets in North America. The company’s flagship properties are located in the Red Lake Mining District of Ontario, Canada, renowned for over 30 million ounces of historic gold production. Other key projects extend into the neighboring Meen-Dempster Greenstone Belt of the Uchi Subprovince. The company’s management team is led by dedicated professionals, aiming to maximize shareholder value while employing modern exploration techniques and principles to achieve its goals.

The mission of StraightUp Resources is to maximize shareholder wealth through mineral discoveries at projects with robust potential, maintain long-lasting partnerships, and continue to focus on the acquisition, development and exploration of mineral resource properties in North America. The company’s objective is to continue to locate and develop economic, precious and base metal properties of merit.

The company’s 10,000-hectare (almost 25,000 acres) RLX Projects are contiguous to various Evolution Mining, Great Bear Resources, Pacton Gold and Dixie Gold properties. Its 2,000-hectare (just under 5,000 acres) Belanger Project is contiguous to Infinite Ore’s Fredart and Garnet/Arrow properties. StraightUp intends to conduct exploration on the RLX North, RLX South, Belanger and Ferdinand Gold properties located in the Red Lake District, a location touted as having one of the best metal-endowed greenstone belts in the world. The Bear Head Gold Project is located within the Meen-Dempster Greenstone Belt of the Uchi Subprovince, approximately 80 kilometers west of the Pickle Lake Gold Camp and 14 km northeast of the former gold mine, Golden Patricia. It amassed 620,000 ounces of gold at an average of 15.2 g/t Au from 1988-1997. The property is bordered by an Australian miner massive gold project. Known gold occurrences are already mapped on the Bear Head property, as are previous drill holes and results. Once the data is re-examined, an exploration budget and subsequent plans will be announced by the company.

Projects

Ontario’s Red Lake Mining District is one of Canada’s most prolific gold mining districts, renowned for its high-grade gold deposits. This is a mining-friendly, politically stable jurisdiction with a skilled labor force and infrastructure specifically built around meeting the needs of the mining industry.

RLX North & South Projects
At over 10,000 hectares, the RLX North and RLX South Projects represent a district-scale exploration opportunity. The RLX North and RLX South Projects are well positioned on-strike to the southeast of the district’s largest gold deposit (Red Lake Gold Mines – Evolution Mining). The project is adjacent to Great Bear Resources’ Sobel Project. Great Bear Resources is also in the process of evaluating the area for significant regional-scale structural controls and has proposed additional work on its neighboring project in the near term. These properties are highly accessible, with the southern boundary only eight kilometers from the paved highway into Red Lake, and can be accessed by forest service roads which traverse throughout the properties.

Belanger Project
Historic exploration work on the 2,000-hectare property has identified three significant surface exposures of gold, copper and silver. Early exploration work will focus on validating historic sampling results and following the occurrences along strike with a view to better understanding the nature and controls on mineralization. The property has excellent forest road access from the town of Ear Falls.

Ferdinand Gold Project
The Ferdinand property is situated within the southeastern extension of the Confederation-Uchi greenstone belt, one of the most metal-endowed greenstone belts in the world by square kilometer. It consists of 17 contiguous mining claims covering approximately 7,143 hectares (17,650 acres), located 13 kilometers northwest of the town of Slate Falls. Access is currently by logging roads, with forestry logging operations scheduled for expansion on the property. StraightUp recently completed a heliborne magnetic survey consisting of 1,994 line-km at 50m line spacings covering the entire property. The MAG survey was designed to provide geological and structural details of a 25km long southeast extension of the Confederation-Uchi greenstone belt along the Fry-Bamaji Deformation Zone.

Bear Head Gold Project
The Bear Head Gold Project comprises 31 mining claims totaling 1,944 hectares (4,800 acres) in the Meen-Dempster Greenstone Belt of the Uchi Subprovince, host to the Golden Patricia former gold mine, which produced 620,000 ounces of gold from 1988 to 1997. The Dorothy Main gold deposit owned by Ardiden lies only one kilometer from the Bear Head Gold Project. The Dorothy Main gold deposit holds noncompliant historical resources of 46,600 ounces of gold at 6.17 g/t Au. The company looks forward to adding the Bear Head Gold Project to its exploration efforts, with a work program to be conducted later in the fall of 2021.

Management Team

Mark Brezer is CEO, President, and Director of StraightUp Resources Inc. He is a successful businessman and holds a Geography/Geology degree from the University of Arizona. He has worked as a Project Manager and has overseen quality control, environmental monitoring and safety programs related to road construction. He has also held roles in media relations and marketing. He has been actively involved in the research and investment of junior mining companies for over 25 years. Time in the field and personal interest led him into extensive first aid training, and he is certified as a paramedic and firefighter.

Daniel Cruz is CFO and Director at StraightUp Resources. He is an experienced financial industry professional, having worked for 12 years as a senior investment advisor at Canadian broker-dealers, where he gained experience in equity research, asset management, investor relations, corporate finance and venture capital. He was one of the youngest Senior Investment Advisors at Canaccord Financial Inc. in 2010. He is also the co-founder and current director of Liquid Media Group Inc., a Nasdaq-listed issuer. During his tenure as CFO, he helped that company list on Nasdaq and raise over $20 million.

Matthew Coltura is a Director at StraightUp Resources. He has a Bachelor of Business Administration from Okanagan College, where he specialized in finance. He has worked in the finance industry for more than three years. Currently, Mr. Coltura is the CFO of Cayenne Capital Corp. He was also a director of PreveCeutical Medical Inc. from July 2016 to September 2019, a director of Sproutly Canada Inc. (formerly Stoneridge Exploration Corp.) from March 2015 to July 2018, and, since March 2018, has worked as a financial specialist at Quip Finance.

StraightUp Resources Inc. (OTCQB: STUPF), closed Wednesday's trading session at $0.22755. The average volume for the last 3 months is 200 and the stock's 52-week low/high is $0.1211/$0.27.

Recent News

• StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) - StraightUp Resources Inc.'s (CSE: ST) (OTCQB: STUPF) Exploration and Expansion Program, A 2021 Outlook
• The Price of Gold Increases After Strong Payroll Data
• MiningNewsBreaks - StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) Is Building for the Future

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

• Avricore Health is developing a variety of pharmacy services that provide lab-quality testing for pre-diabetes and cardiovascular concerns
• The company’s trademarked HealthTab platform makes advanced testing technologies available to partner pharmacies and, through them, to patients at accessible point-of-care (“POC”) locations
• HealthTab’s partnership with Abbott Diagnostics in Canada also has the potential to expand to virus testing for COVID, RSV, influenza A and B, and strep
• The company has located the systems in Ontario and British Columbia through an agreement with large national pharmaceutical chain Shoppers Drug Mart, and anticipates expansion to other Shoppers Drug sites with 600 locations established by the end of 2023
• Avricore also expects to forge agreements that will take HealthTab’s POC testing to pharmacies in the United States, United Kingdom and European Union

Health diagnostics solutions innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is celebrating its achievement of key milestones this year, building on its initial agreement with Canada’s Shoppers Drug Mart pharmaceutical chain to make its platform technology accessible to patients across the country.

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Wednesday's trading session at $0.1171. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $0.068/$0.48562.

Recent News

• Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) - Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Builds Upon Successes with Key 2021 Milestones, Aims for International Growth of POC Lab Testing Model
• InvestorNewsBreaks - Avricore Health Inc.'s (TSX.V: AVCR) (OTCQB: AVCRF) HealthTab(TM) Enters Agreement to Support Patients with Key Insight into Renal Function
• Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) and Its Commitment to Patients

DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF)

The QualityStocks Daily Newsletter would like to spotlight DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF).

• Hiring the wrong individual or placing a good candidate on the wrong team holds dire consequences for organizations.
• PPI evaluates, improves a company’s workforce, brand and culture by revealing the personality traits and sentiment buried in human expression.
• With PPI, savvy organizations can make better hiring decisions, reduce employment attrition and improve workplace culture. 

Hiring the right talent and personality for a job is vital for employees — and employers — to be engaged and happy in the workplace, yet it can be hard to know when the person and position are perfect for each other. According to a Forbes article, artificial intelligence (“AI”) technology may be just what companies need to make those types of decisions (https://ccw.fm/v6E9X). That’s good news for DigiMax Global (CSE: DIGI) (OTC: DBKSF), an artificial intelligence technology and services company, whose Projected Personality Interpreter can be effectively used by employees to identify the ideal employees.

DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF) is an artificial intelligence technology and services company producing and leveraging predictive indicators across various industries and verticals.

The company offers financial, business, and human capital AI predictive solutions to businesses, institutions, and consumers to improve decision-making.

The DigiMax core solutions are:

1. CryptoHawk AI – CryptoHawk is a deep learning AI solution (SaaS) that monitors and analyzes live select cryptocurrencies and financial markets. The CryptoHawk AI solution is offered to retail clients as a monthly subscription. Generated data provides subscribers with price trend predictions for better investment strategies.
2. Cryptocurrency Hedge Fund – A long/short cryptocurrency hedge fund for high net worth, institutional, and family office clients was launched on September 1, 2021. The company’s crypto hedge fund earns clients’ management and overall performance fees.
3. Projected Personality Interpreter (PPI) – DigiMax solutions utilize AI to provide comparative insights for better hiring decisions, reduced employment attrition, improved workplace culture, and augmented human and financial predictive services by measuring and correlating personal attributes.
4. Navee Predict – DigiMax data scientists provide companies with the unprecedented power of enhancing decision-making by analyzing, detecting changes and forecasting patterns.

The company’s team has extensive experience in finance, trading, machine learning (ML), neural language processing, AI, big data, and cryptocurrency technology. DigiMax leverages AI and its expert team to translate data into actionable predictive insights across the financial, business, and human dimensions, enhancing the decision-making capacity of organizations. DigiMax is an official IBM Watson partner with more than 30 years in data science and artificial intelligence.

Solutions

Business and Financial Capital Solutions

CryptoHawk AI

CryptoHawk.ai is a cryptocurrency price and trend prediction solution offered as a web application (https://cryptohawk.ai) and a mobile application by the end of 2021. The value for the user is to capture gains and take advantage of volatility while reducing risk and engaging in smarter and simpler trading.

The key features:

• Trend Prediction Indicator (“TPI”)
  The TPI is a superior model that leverages the cryptocurrencies analyzed by the AI and other market-driven data and policies to produce actionable predictions in the form of:
  • Prediction cards
  • Cryptocurrency graphs with optional market indicators
  • Email/SMS alerts
• Trend Watch
  Trend Watch is a one-week look ahead machine learning prediction for a select portfolio of mature cryptocurrencies. Trend Watch predicts a trend being UP or DOWN and provides a price target. Users have access to:
  • A list of select cryptocurrencies with predictive graphs

The system alerts investors through email and text messages when a price trend changes, allowing users to act confidently.

Cryptocurrency Hedge Fund

On September 1, 2021, DigiMax launched its Cryptocurrency Hedge Fund to offer high net worth, institutional, and family office clients a fully systematic long/short active investment into a basket of cryptocurrencies capitalizing on crypto volatility and powered by proprietary trading algorithms. The official launch is expected in the coming months.

The fund is led by 40-year hedge fund veteran Ian Hamilton and has an experienced investment and fund management team. This actively managed fund provides an excellent opportunity for larger investors to gain exposure to cryptocurrencies.

AI Business Prediction as a Service

The company offers predictive insights to businesses through automation and its innovative and proprietary AI and ML technology. Traditional models are expensive, because they are created and developed by data scientists dedicated to solving specific business questions that require costly customization and weeks, if not months, of development. With DigiMax, companies have access to solutions and services at a fraction of the price of traditional and experimental approaches. By combining AI with ML prediction technology, the company delivers insights on:

• Sales forecasts
• Optimal inventory levels
• Supply chain management
• Invoice payment projections
• Targeted segmentation for marketing campaigns

Human Capital Solutions

AI-Powered Projected Personality Interpreter

The Projected Personality Interpreter (“PPI”) evaluates and improves customers’ workforce, brand and culture by revealing the personality traits and sentiment buried in human expression. The PPI empowers organizations with comparative insight for better hiring decisions, reducing employment attrition and improving workplace culture.

PPI provides a comprehensive and complete solution, offering:

• Recruitment campaign management
• Custom questionnaires, desirable traits recipes, and group likenesses
• Detailed personality reports to compare and contrast peers
• API for advanced integration with alternative systems of record

DigiMax leverages IBM Watson and a custom algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, providing hiring managers with a comprehensive report that improves decision making and takes the bias out of the process. The company’s solution is currently in use by 17 law enforcement agencies in North America and is used across the 10 global recruitment brands of Shepherd Search Group.

Market Overview

The AI industry has a five-year CAGR of 18.4%, with revenues projected to reach $37.9 billion by 2024. Some more optimistic forecasts have the market worth as much as $15 trillion by 2030. It’s estimated that 80% of all emerging technologies in 2021 have AI foundations. About 40% of all businesses use AI in their operations. According to Industry Ark, artificial intelligence use in the recruitment market was valued at $580 million in 2019.

Management Team

Chris Carl, CEO

Chris Carl has over 20 years of experience as a public-company CEO and has built several successful businesses across multiple categories. He has a proven ability to lead and has a track record of execution, revenue growth, and value creation.

Thierry Hubert, CTO

Thierry Hubert has 30 years of technology experience with Fortune 100 companies worldwide and is an early pioneer in applying artificial intelligence to solve big data and unstructured information challenges with IBM as a Director of R&D in emerging technology, knowledge management, and process innovation. He has received awards, recognitions, and grants that contributed to his ongoing collaboration with industry leaders.

David Bhumgara, CFO

David Bhumgara is a senior finance executive with over 25 years of leadership experience and proven expertise in finance, financial reporting, accounting, corporate finance, budgeting, financial modeling, and mergers & acquisitions.

Damon Stone, Trading Strategy Advisor

Damon Stone is an experienced stock and crypto trader who works very closely with the Cryptodivine.ai data science team as a subject matter expert. During 15 years at Merrill Lynch as a market maker and proprietary trader, he traded many different sectors, culminating in heading up a $250 million trading desk.

Ross Power, Senior Innovation Engineer
Ross Power is an experienced technical system architect with a demonstrated history of working on advanced technologies, including AI algorithms, IoT solutions, 3D printing, Innovation in BCI (Brain-Computer Interfacing), and RC flight and navigation systems.

DigiMax Global Inc. (DBKSF), closed Wednesday's trading session at $0.07225, on 49 volume with 2 trades. The average volume for the last 3 months is 49 and the stock's 52-week low/high is $0.05/$0.70.

Recent News

• DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) - DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) Offers AI Solution to Improve Company Workforce, Brand and Culture
• CryptoNewsBreaks - DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) Empowering Clients to Make Better Decisions Through Actionable Predictive Insight
• DigiMax Global Inc.'s (CSE: DIGI) (OTC: DBKSF) AI-Powered Hedge Fund Gives Investors Exposure to Crypto

RYAH Group Inc. (CSE: RYAH)

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc. (CSE: RYAH).

Earlier this week, President Joseph Biden signed a large-scale infrastructure outlining provisions that will permit scientists to conduct research on the cannabis that consumers buy from state-legal dispensaries. This bill encourages states that have enacted laws to legalize the herb to educate individuals on impaired driving. The bill also stipulates that the secretary of Health and Human Services and the attorney general will need to collaborate with the secretary of transportation to compile a public report within two years of the measure’s enactment that will include recommendations on permitting researchers to access retail-level cannabis to study impaired driving. When the studies on dispensary-sourced marijuana envisaged in this law commence, they would greatly benefit from the AI tools designed by companies such as RYAH Group Inc. (CSE: RYAH) since such tools help a lot to correlate and validate clinical study findings.

RYAH Group Inc. (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

RYAH Group Inc. (CSE: RYAH), closed Wednesday's trading session at $0.06, even for the day, on 496,000 volume with 38 trades. The average volume for the last 3 months is 793,200 and the stock's 52-week low/high is $0.055/$0.20.

Recent News

• RYAH Group Inc. (CSE: RYAH) - 420 with CNW - Biden Signs Infrastructure Measure to Allow Studies on Cannabis from State-Legal Dispensaries
• Data Analytics Finds Disparities in Pregnancy Outcomes
• 420 with CNW - New Cannabis Initiative to Push for Federal Legalization Launched

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

• An ever-increasing demand for energy is fueling the focus on sustainable energy solutions.
• UUUU is proud to produce the raw materials that make numerous clean-energy and advanced technologies possible.
• Energy Fuels began producing rare earths in 2021, which are used in electric vehicles, renewable energy, batteries and other technologies.

As the world becomes more focused on and committed to clean energy and sustainability, companies in every sector are recognizing the importance of advancing ESG (environmental, sustainability, and governance) priorities. A leading U.S.-based uranium mining company Energy Fuels (NYSE American: UUUU) (TSX: EFR) places a high priority on its efforts to produce raw materials that support global clean-energy efforts. BNF Capital director Sean Benson has revealed that the Perrodo family decided to invest into Rolls Royce’s small modular reactor technology plans as the energy transition will not be possible without the use of nuclear power. The billionaire French oil family, whose fortune was built on investments in gas and oil, is one-half of the pair of private backers of the aero-engine group’s plan for mini nuclear power plants. This move is part of a series of investments based on a revival for nuclear power, with Benson noting that the family believes uranium will play a crucial role in meeting the carbon targets for net zero that have been set globally. The involvement of the French millionaires in the modular reactor project is an indicator that companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are likely to see increased demand for the energy metal they extract due to the evolving technology being used to generate nuclear energy.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

• White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
• Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
• Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

• Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
• Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
• Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

• La Sal Complex (Utah)
• Whirlwind Mine (Colorado/Utah)
• Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Wednesday's trading session at $9.4, off by 0.529101%, on 2,392,547 volume with 15,220 trades. The average volume for the last 3 months is 2.387M and the stock's 52-week low/high is $1.925/$11.39.

Recent News

• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) - InvestorNewsBreaks - Flora Growth Corp. (NASDAQ: FLGC) Secures $34.5M in Underwritten Public Offering
• Billionaires Bankroll Planned Rolls-Royce Modular Uranium Reactors
• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Produces Raw Materials for Numerous Clean-Energy, Advanced Technologies

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced the closing of its underwritten public offering of 11,500,000 units, with each unit consisting of one common share of the company and one-half warrant; each whole unit warrant entitling the holder to purchase one common share. The units sold includes an additional 1,500,000 pursuant to the exercise in full of the overallotment option granted to the underwriters. Flora secured $34,500,000 in gross proceeds, with each of the units sold at a public offering price of $3.00. The unit warrants will be immediately exercisable at an exercise price of $3.75 per share and will expire five years from the date of issuance. A.G.P./Alliance Global Partners acted as the sole book-running manager for the public offering and BMO Capital Markets and Roth Capital Partners acted as co-managers. MKM Partners served as a financial advisor to the company. To view the full press release, visit https://ibn.fm/x0KxF

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

• Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
• Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
• Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

• Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
• Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
• Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $2.12, off by 1.8519%, on 1,986,799 volume with 8,448 trades. The average volume for the last 3 months is 1.876M and the stock's 52-week low/high is $2.0302/$21.45.

Recent News

• Flora Growth Corp. (NASDAQ: FLGC) - 420 with CNW - Veterans Continue Having Trouble Accessing Medical Cannabis Despite Its Legality
• Flora Growth Prices $30 Million Offering
• 420 with CNW - How the Fashion Industry Is Giving Hemp Fiber a Hand Up

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

• MCOA just signed an LOI with VapeTV UK and Jasleen Enterprises for the launch of VapeTV U.S.
• This new company is set to offer in-store advertising within retail vape stores
• It will capitalize on the growing CBD industry and the ever-increasing demand for in-store media advertising in the United States

Marijuana Company of America (OTC: MCOA) has announced the signing of a non-binding letter of intent (“LOI”) that marks the beginning of the process to form a new in-store advertising brand named VapeTV US, Inc. (https://cnw.fm/jfcGM). 

Marijuana Company of America Inc. (OTC: MCOA) operates and invests in the cannabis sector directly. The company’s diverse operations include cDistro, one of the THC, hemp & CBD cannabis industries’ fastest growing distribution companies; hempsmart™, a premium CBD company; and VBF Brands Inc., a cannabis nursery cultivation facility in Salinas, California, that is a cultivator and distributor utilizing its own growing systems to produce desirable cannabis clones.

MCOA continues to grow its business while remaining fiscally conscious and further establishing itself in the legalized cannabis THC, hemp & CBD industries by offering unique exposure to the global cannabidiol sector. The company intends to continue to leverage its premium brand hemp-based products with investments in and collaboration with existing and new strategic partners.

Marijuana Company of America offers investors the opportunity to be at the forefront of innovation in the legal cannabis and industrial hemp industries.
During the summer of 2021, the U.S. witnessed the introduction of the most comprehensive cannabis reform ever proposed at the federal level, as well as ongoing state-level liberalization. The investments MCOA has made will position the company to drive the expected strongest revenue growth in the company’s history.

MCOA strives to develop a comprehensive selection of synergistic companies that provides consistent value to its shareholders. Furthermore, its vertically integrated business model provides companies and partners with the best opportunities for rapid growth. It is MCOA’s attention to detail in producing premium products and adhering to the best business practices that distinguish it among the leaders of cannabis products in the global marketplace.

MCOA is building a portfolio of investments and joint ventures that represent the highest integrity and professionalism in the legal cannabis and industrial hemp markets. MCOA is a model for entrepreneurs and businesses that share its common goals and philosophies of not only creating value for investors but also creating an environment for businesses to improve the quality of life of customers through sustainable alternatives to many products currently on the market.

Partnerships and Investments

MCOA has partnered with and invested in a portfolio of companies operating in the cannabis sector. These include:

Cannabis Global Inc.

Cannabis Global Inc. (OTC: CBGL) is an emerging force in the cannabis marketplace with growing product and intellectual property portfolios. CBGL is marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport, and tracking, and is also the developer and marketer of the Hemp You Can Feel™ brand.

Eco Innovation Group Inc.

Eco Innovation Group Inc. (OTC: ECOX) works with inventors and other professionals to nurture and catalyze the most innovative and impactful products and services and deliver those innovations to market. ECOX is dedicated to developing and commercializing successful products.

MCOA’s investment supports Eco Innovation’s cutting-edge extraction technology. ECOX’s extraction processes utilize a proprietary formulation to extract valuable bioactive compounds from cannabidiol (CBD) combined with plant-based materials to create a fluid and cost-effective output.

Together, both companies are positioned to identify and accelerate the development of new varieties of hemp-based products and distribute them worldwide.

Natural Plant Extract

MCOA owns a direct investment interest in Natural Plant Extract (NPE), which operates a licensed cannabis manufacturing and distribution business in Lynwood, California. NPE holds a Type 7 California manufacturing and distribution license, allowing for cannabis product distribution anywhere in the State of California.

Wholly Owned Subsidiaries

hempsmart™

hempsmart™ is a CBD company focused on creating and promoting the most effective, best tasting, and highest quality products on the market.

In 2021, hempsmart expanded into the global marketplace and announced a rebrand that featured a fresh take on its packaging and a social media campaign to engage customers via Instagram, Twitter, TikTok, and more, which has now generated a new loyal group of followers.

hempsmart premier products include its Smart Drops (CBD Drops), Neuro Smart (Patented Brain Pills), and Smart Cream (Pain Cream) brands. These organic, plant-based products help to manage anxiety, pain and insomnia, without the inclusion of THC.

cDistro

cDistro distributes CBD brands, along with smoke and vape shop-related products, to wholesalers, c-stores, specialty retailers, and consumers in North America.
cDistro was chosen as one of the first to distribute Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family.
The initial product offering will include a range of functional mushroom tinctures, including species such as cordyceps, lion’s mane, chaga, reishi and turkey tail, that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement.

VBF Brands Inc.

MCOA recently completed the acquisition of VBF Brands Inc., a fully licensed marijuana cultivator and distributor based in Salinas, California. VBF utilizes its own growing systems to produce desirable cannabis clones that are designed to assist growers by reducing uncertainty and enhancing the likelihood of a successful cultivation harvest. Cannabis clones carry the exact same genetic potential as their mother plants and have similar cannabinoid and terpene profiles when grown properly.

This subsidiary will immediately work toward increasing production at its Salinas facility, which also offers exponential growth potential with other nearby properties that MCOA has an option to participate in as part of the acquisition.

Market Outlook

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will increase opportunities for this market.

According to a Grand View Research report, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028. That would put the market value at roughly $30 billion by 2025.

The report cites the growing number of countries that are legalizing cannabis as a driver for surging demand. It also points out the use of medical marijuana for various ailments is gaining momentum worldwide. Medical marijuana is prescribed for patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s and other neurological disorders. The demand for cannabis oil is also increasing rapidly, especially among countries with legalized medical marijuana.

Management Team

Jesus Quintero is the CEO and Chairman of MCOA. From January 2013 to September 2014, he was the Chief Financial Officer of Brazil Interactive Media Inc. Since 2011, he has served as a financial consultant to several multimillion-dollar businesses in South Florida. He has extensive experience in public company reporting and SEC/SOX compliance and held senior finance positions with Avnet Inc., Latin Node Inc., Globetel Communications Corp., and Telefonica of Spain. His prior experience also includes positions at Price Waterhouse and Deloitte & Touche. He holds a B.S. in Accounting from St. John’s University and is a certified public accountant.

Marijuana Company of America Inc. (MCOA), closed Wednesday's trading session at $0.00225, off by 6.25%, on 30,209,282 volume with 182 trades. The average volume for the last 3 months is 25.053M and the stock's 52-week low/high is $0.0015/$0.0398.

Recent News

• Marijuana Company of America Inc. (OTC: MCOA) - Marijuana Company of America Inc. (MCOA) Set to Launch VapeTV U.S. in a Three-Way Partnership
• InvestorNewsBreaks - Marijuana Company of America Inc. (MCOA) Achieves Highest Quarterly Revenue Since Inception in Q3 2021
• Marijuana Company of America Inc. (MCOA) Is 'One to Watch'

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

The state of Pennsylvania may become the new psychedelic research hub in the United States if a measure that was introduced in the state’s House of Representatives in October is approved. The measure, dubbed the Public Health Benefits of Psilocybin Act, will establish a framework for research on psilocybin to be conducted in order to determine its effectiveness as a treatment for various mental health conditions. Psilocybin is the active compound found in hallucinogenic mushrooms. The Health Committee will be voting on the initiative this coming week. The prime sponsor of the measure is Tracy Pennycuick, an army veteran. It has 20 cosponsors, comprising of both Republicans and Democrats. The measure also directs that the Department of Health in the state prioritize clinical trials involving retired first responders, military veterans and members of their family. In addition to this, the initiative would also allow the Department of Health in the state to license a number of growers of hallucinogenic mushrooms, which will be used for clinical research. Those increased amounts of psychedelics intended for research purposes are badly needed given that a lot more entities are following the path set by early adopters, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), on matters of conducting R&D activities on psychedelic compounds.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $1.42, off by 3.4014%, on 1,751,792 volume with 5,832 trades. The average volume for the last 3 months is 1.746M and the stock's 52-week low/high is $0.54/$3.38.

Recent News

• Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) - Psilocybin Mushroom Measure May Make Pennsylvania New Psychedelic Research Hub
• InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities
• Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves 'One Step Closer' to Creating Best Therapy for Mental Health